Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for treating C-MET associated cancers

A correlation, cancer technology, applied in the direction of drug combination, medical raw materials derived from bacteria, medical raw materials from fungi, etc.

Inactive Publication Date: 2017-08-29
YEASTERN BIOTECH
View PDF10 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, it has not been explored whether any FIP can block c-Met-dependent signaling

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating C-MET associated cancers
  • Methods and compositions for treating C-MET associated cancers
  • Methods and compositions for treating C-MET associated cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] Example 1: Establishing a FIP- gts Patient-Derived HCC for Preclinical Trials

[0073] Clinically derived HCC cell lines were established from a portion of surgically obtained HCC tissue with patient consent and approval by the Buddhist Tzu Chi General Hospital Research Ethics Committee (IRB101-62). Briefly, HCC tissues were pretreated with collagenase, followed by selection of HCC cell lines on mitomycin-treated NIH3T3 feeder layers for a total of 4-6 passages. Obtain homogeneous populations of HCC cells and test their sustained proliferation (over 20 passages) and metastatic potential in vitro and in vivo. Characterization of HCC tumor cell lines was confirmed by detection of HCC tumor markers such as Glypican 3 (GCP3) after more than 40 passages.

[0074] Patient-derived HCC cell lines were established and their phenotypes characterized. Morphologies of nine HCCs (referred to as HCC329, 328, 326 and 340, 353, 365, 363, 372, 274) were shown ( Figure 1A ). Sever...

Embodiment 2

[0075] Embodiment 2: Wound healing migration test

[0076] HCC cells were cultured on 24-well dishes provided with wound healing culture inserts until the cells became confluent, then cells were serum starved for 24 hours, after which the culture inserts were removed. After appropriate processing, pictures were taken using a phase-contrast microscope at the indicated times. The quantitative analysis of the motility of the HCC cell line described in Example 1 was performed by directly counting the cells that migrated to the blank area at 48 hours using the Image J. software taken from the NIH website. result in Figure 1B show. In general, mesenchymal HCCs are more mobile than epithelial HCCs. Among them, mesenchymal phenotypes HCC329 and HCC372 exhibited the highest activity, and epithelial phenotypes HCC340 and HCC374 exhibited the lowest activity ( Figure 1C ).

Embodiment 3

[0077] Example 3: Analysis of signaling in patient-derived HCCs

[0078] The status of key signaling members involved in tumor progression of HCCs, including c-Met, ERK, JNK and AKT, was further examined in the patient-derived cell line established in Example 1 and the commonly used HCC cell line HepG2. Total protein was collected from these cells and subjected to immunoblot analysis using GAPDH as a loading control. Antibodies to p-c-Met, p-JNK, p-ERK, p-paxillin (p-paxillin; S178), GAPDH and ERK were purchased from Santa Cruz Biotechnology (California, USA). Band intensities on the blots were quantified using Image J. software. figure 2 Results shown are representative of 2 reproducible experiments.

[0079] Such as figure 2As shown, c-Met (β subunit, M.W. 140kD) was highly expressed in HCC 372, 340 and HepG2, slightly detected in HCC374, but not observed in other cell lines. Dimerization of c-Met is known to activate the phosphorylation of a tyrosine residue (Tyr1234)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
purityaaaaaaaaaa
Login to View More

Abstract

The present invention provides the use of a fungal immunomodulatory protein (FIP) in manufacturing a medicament for inhibiting hepatocyte growth factor receptor (HGFR) activity in a cell, and for treating HGFR-associated cancer.

Description

[0001] priority claim [0002] This application claims priority to US Patent Application No. 62 / 044,415 filed on September 2, 2014, the entire contents of which are incorporated herein by reference. Part of the information disclosed in this application was published online in PLoS ONE on January 21, 2015, titled "Preclinical Trials for Prevention of Tumor Progression of Hepatocellular Carcinoma by LZ-8 Targeting c-Met Dependent and Independent Pathways". technical field [0003] The present invention relates to the use of fungal immunoregulatory protein (FIP) in the treatment of cancer, especially c-Met-related cancer, more particularly hepatocellular carcinoma; relates to the use of FIP in inhibiting tumor growth, cancer, especially c-Met-related cancer Use for migration, metastasis or recurrence of cancer, more particularly hepatocellular carcinoma. The invention also relates to methods and compositions for blocking c-Met signaling. Background technique [0004] Hepatoce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61K36/06A61K35/74A61P37/04A61P3/10
CPCA61K36/064A61K38/168A61P3/10A61P35/00A61P37/04A61K35/74
Inventor 吴文陞吴家如胡志棠尤仁音马珮羚陈子智
Owner YEASTERN BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com